1.57

0.64% 0.01

After Hours: 1.63 0.06 +3.82%

Proqr Therapeutics N V (PRQR)

Overview News Price History Option Chain Discussions Forecast

Proqr Therapeutics N V stock is traded at $1.57, with a volume of 440.64K. It is up +0.64% in the last 24 hours and up +1.29% over the past month. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Previous Close:

$1.56

Open:

$1.59

24h Volume:

440.64K

Relative Volume:

0.78

Market Cap:

$165.42M

Revenue:

$17.91M

Net Income/Loss:

$-47.66M

P/E Ratio:

-3.4536

EPS:

-0.4546

Net Cash Flow:

$-62.63M

1W Performance:

+9.79%

1M Performance:

+1.29%

6M Performance:

-33.47%

1Y Performance:

-5.99%

1-Day Range:

$1.539

$1.64

1-Week Range:

$1.40

$1.64

52-Week Range:

$1.33

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name

Proqr Therapeutics N V

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

Address

Employee

187

Twitter

@proqr

Next Earnings Date

2026-05-14

Latest SEC Filings

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRQR Proqr Therapeutics N V	1.57	164.37M	17.91M	-47.66M	-62.63M	-0.4546
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	Oppenheimer	Outperform
Apr-29-25	Resumed	Cantor Fitzgerald	Overweight
Apr-29-25	Initiated	Evercore ISI	Outperform
Mar-10-25	Upgrade	Citigroup	Neutral → Buy
Jan-10-25	Initiated	Oppenheimer	Outperform
Oct-29-24	Upgrade	Raymond James	Outperform → Strong Buy
Nov-08-23	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-30-23	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Dec-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-14-22	Downgrade	Citigroup	Buy → Neutral
Feb-11-22	Downgrade	Raymond James	Strong Buy → Mkt Perform
Feb-11-22	Downgrade	Stifel	Buy → Hold
Feb-01-22	Initiated	Raymond James	Strong Buy
May-03-21	Initiated	Stifel	Buy
Mar-25-21	Reiterated	Citigroup	Buy
Nov-03-20	Resumed	Cantor Fitzgerald	Overweight
Mar-12-19	Reiterated	Chardan Capital Markets	Buy
Dec-19-18	Initiated	RBC Capital Mkts	Outperform
Nov-15-18	Initiated	Citigroup	Buy
Sep-19-18	Initiated	Evercore ISI	Outperform
Sep-26-17	Reiterated	JMP Securities	Mkt Outperform
Jun-20-16	Initiated	Chardan Capital Markets	Neutral
Oct-15-14	Initiated	Deutsche Bank	Buy
Oct-13-14	Initiated	H.C. Wainwright	Buy

View All

Proqr Therapeutics N V Stock (PRQR) Latest News

May 24, 2026

ProQR (PRQR) Eyes Next Move After Holiday Ahead of AX-0810 Data - Bez Kabli

May 24, 2026

May 22, 2026

ProQR Therapeutics Q1 2026 Earnings: Narrower Net Loss, No Revenue as Pipeline Progress Drives Stock GainsWall Street Picks - Newser

May 22, 2026

May 21, 2026

Cash per share of ProQR Therapeutics N.V. – LS:A12B97 - TradingView

May 21, 2026

PRQR Stock Price, Quote & Chart | PROQR THERAPEUTICS NV (NASDAQ:PRQR) - ChartMill

May 21, 2026

May 19, 2026